Replicate Study designs [Outliers]

posted by Ohlbe – France, 2014-01-08 15:24 (3849 d 01:08 ago) – Posting: # 12146
Views: 13,909

Dear Balakotu,

❝ So, how can we justify those two subjects data as outliers/anomalous and how to perform statistical analysis in such a case?

For which authority ?

In the EMA guideline (§4.1.8.) the answer is clear:

Exclusion of data cannot be accepted on the basis of statistical analysis or for pharmacokinetic reasons alone, because it is impossible to distinguish the formulation effects from other effects influencing the pharmacokinetics.

The exceptions to this are:

1) A subject with lack of any measurable concentrations or only very low plasma concentrations for reference medicinal product. A subject is considered to have very low plasma concentrations if its AUC is less than 5% of reference medicinal product geometric mean AUC (which should be calculated without inclusion of data from the outlying subject). The exclusion of data due to this reason will only be accepted in exceptional cases and may question the validity of the trial.

So looking at your case, the conclusion for an EU submission is simple: the study fails.


Complete thread:

UA Flag
 Admin contact
23,119 posts in 4,859 threads, 1,647 registered users;
38 visitors (1 registered, 37 guests [including 10 identified bots]).
Forum time: 17:33 CEST (Europe/Vienna)

You can’t really say “similar” if it’s the same again you want.
“Similar” means something different.    Anthony Burgess

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz